Impact Biomedicines, Inc. Sustainability Profile
Impact Biomedicines, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for patients with serious diseases. Founded in 2015, the company has rapidly established itself in the biopharmaceutical industry, particularly in the fields of haematology and oncology. Impact Biomedicines is renowned for its unique approach to drug development, with a portfolio that includes cutting-edge treatments aimed at addressing unmet medical needs. The company’s flagship product, a novel therapy for myelofibrosis, has garnered significant attention for its potential to improve patient outcomes. With a commitment to scientific excellence and patient-centric solutions, Impact Biomedicines has positioned itself as a leader in the biomedicine sector, achieving notable milestones in research and development that underscore its dedication to advancing healthcare.
DitchCarbon Score
How does Impact Biomedicines, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Impact Biomedicines, Inc.'s score of 71 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Impact Biomedicines, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Bristol-Myers Squibb Company, from which it inherits climate commitments and initiatives. Bristol-Myers Squibb has established various climate initiatives, including Science Based Targets Initiative (SBTi) targets and participation in the Carbon Disclosure Project (CDP). These initiatives aim to reduce greenhouse gas emissions across their operations, which may indirectly influence Impact Biomedicines' climate strategy. As a current subsidiary of Bristol-Myers Squibb, Impact Biomedicines aligns with the broader sustainability goals set by its parent company, although specific reduction targets or achievements for Impact Biomedicines have not been disclosed. The company is expected to adhere to the climate commitments and performance metrics established by Bristol-Myers Squibb, which are designed to enhance environmental responsibility and reduce carbon footprints across their operations. In summary, while specific emissions data for Impact Biomedicines is not available, the company is positioned within a framework of climate commitments inherited from Bristol-Myers Squibb, reflecting a commitment to sustainability and carbon reduction in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Impact Biomedicines, Inc.'s Industry?
How Carbon Intensive is Impact Biomedicines, Inc.'s Location?
Impact Biomedicines, Inc.'s Scope 3 Categories Breakdown
Impact Biomedicines, Inc.'s Scope 3 emissions, which decreased by 1% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
Impact Biomedicines, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Impact Biomedicines, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
